Personalized Ocular Pain Management System

A next-generation system for personalized ocular pain management, integrating wearable sensors, micro-dosing devices, and AI-driven analytics to provide targeted and sustained relief from ocular pain.

The original patent disclosed the use of prostacyclin antagonists for treating ocular surface nociception, but it had limitations in terms of personalized treatment and real-time monitoring. The present inventive concept addresses these limitations by introducing a wearable sensor and micro-dosing device that work in tandem to detect and respond to ocular surface nociception in real-time, providing a more effective and personalized treatment approach.

The system comprises a portable, wearable sensor that detects changes in ocular surface nociception and transmits data to a micro-dosing device, which delivers a tailored amount of a prostacyclin antagonist to the affected eye. The system can be integrated with AI-driven analytics to predict and prevent ocular pain, and can be used in conjunction with novel formulations of prostacyclin antagonists that release the antagonist in response to changes in ocular surface pH. Additionally, the system can be expanded to include smart contact lenses and neural interfaces that provide real-time relief from ocular discomfort.

The present inventive concept introduces a novel combination of wearable sensors, micro-dosing devices, and AI-driven analytics to provide personalized ocular pain management, which is not disclosed in the original patent. The use of wearable sensors and micro-dosing devices to detect and respond to ocular surface nociception in real-time is a significant departure from the original patent's approach, and the integration of AI-driven analytics provides an additional layer of sophistication and personalization.

Alternative embodiments of the inventive concept could include the use of different types of sensors, such as electroencephalography (EEG) or functional near-infrared spectroscopy (fNIRS), to detect changes in ocular surface nociception. The system could also be adapted for use in veterinary medicine, or integrated with other therapeutic modalities, such as electrical stimulation or phototherapy, to provide a more comprehensive treatment approach.

The present inventive concept has significant commercial potential in the ophthalmic industry, with potential applications in the treatment of dry eye disease, ocular surface injuries, and other conditions characterized by ocular pain. The system's ability to provide personalized and targeted relief from ocular pain could make it an attractive option for patients and clinicians alike, and its potential integration with AI-driven analytics could provide a competitive advantage in the market.